Scailyte announces final closing of pre-series A financing Startupticker.ch | The Swiss Startup News channel
Summary
The pre-series A financing round will allow Scailyte to develop faster their assays in the rapid-emerging single-cell data technology field. The start-up works on discovering ultrasensitive biomarkers and develops in-vitro diagnostics (IVD) using single-cell technologies and their proprietary single-cell data analysis platform ScaiVision. It includes candidates for biomarkers for Endometriosis and CTCL with a market potential of several hundred million Francs for each of these diagnostics. Furthermore, Scailyte enjoys strong support in the medical expert community” says Susanne Schorsch, Investment Manager at investiere. With the support of strong partners like Swisscom Ventures, 4FO and HEMEX, we will continue to grow in the fast-emerging single-cell analysis field, enabling various clinical applications of single-cell data “.